FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057366353> ?p ?o ?g. }

• W2057366353 endingPage "244" @default.
• W2057366353 startingPage "240" @default.
• W2057366353 abstract "A study of genome evolution in a metastatic breast cancer bearing an activating PIK3CA mutation, following treatment with the PI(3)Kα inhibitor BYL719, shows that all metastatic lesions, when compared to the pre-treatment tumour, had lost a copy of PTEN; parallel genetic evolution of separate sites with different PTEN genomic alterations had led to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition. The emergence and expansion of resistant clonal subpopulations is a major challenge facing the field of targeted therapeutics. Here, the authors study genome evolution in a metastatic breast cancer bearing an activating PIK3CA mutation, following treatment with the phosphatidylinositol-4,5-bisphosphate 3-kinase alpha subunit (PI(3)Kα) selective-inhibitor BYL719. Fourteen metastatic sites were sequenced to reveal that all metastatic lesions, when compared to the pre-treatment tumour, had lost a copy of the gene for the tumour suppressor phosphatase PTEN. Resistance to BYL719 was associated with additional and different PTEN genetic alterations, resulting in loss of PTEN expression. Based on these observations and additional functional characterization, the authors conclude that parallel genetic evolution of separate sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition. Broad and deep tumour genome sequencing has shed new light on tumour heterogeneity and provided important insights into the evolution of metastases arising from different clones1,2. There is an additional layer of complexity, in that tumour evolution may be influenced by selective pressure provided by therapy, in a similar fashion to that occurring in infectious diseases. Here we studied tumour genomic evolution in a patient (index patient) with metastatic breast cancer bearing an activating PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha, PI(3)Kα) mutation. The patient was treated with the PI(3)Kα inhibitor BYL719, which achieved a lasting clinical response, but the patient eventually became resistant to this drug (emergence of lung metastases) and died shortly thereafter. A rapid autopsy was performed and material from a total of 14 metastatic sites was collected and sequenced. All metastatic lesions, when compared to the pre-treatment tumour, had a copy loss of PTEN (phosphatase and tensin homolog) and those lesions that became refractory to BYL719 had additional and different PTEN genetic alterations, resulting in the loss of PTEN expression. To put these results in context, we examined six other patients also treated with BYL719. Acquired bi-allelic loss of PTEN was found in one of these patients, whereas in two others PIK3CA mutations present in the primary tumour were no longer detected at the time of progression. To characterize our findings functionally, we examined the effects of PTEN knockdown in several preclinical models (both in cell lines intrinsically sensitive to BYL719 and in PTEN-null xenografts derived from our index patient), which we found resulted in resistance to BYL719, whereas simultaneous PI(3)K p110β blockade reverted this resistance phenotype. We conclude that parallel genetic evolution of separate metastatic sites with different PTEN genomic alterations leads to a convergent PTEN-null phenotype resistant to PI(3)Kα inhibition." @default.
• W2057366353 created "2016-06-24" @default.
• W2057366353 creator A5002819777 @default.
• W2057366353 creator A5003417891 @default.
• W2057366353 creator A5004300577 @default.
• W2057366353 creator A5004669792 @default.
• W2057366353 creator A5007116190 @default.
• W2057366353 creator A5011125370 @default.
• W2057366353 creator A5018555557 @default.
• W2057366353 creator A5019032346 @default.
• W2057366353 creator A5023891950 @default.
• W2057366353 creator A5025451142 @default.
• W2057366353 creator A5033930240 @default.
• W2057366353 creator A5034256147 @default.
• W2057366353 creator A5035700326 @default.
• W2057366353 creator A5037092952 @default.
• W2057366353 creator A5042749420 @default.
• W2057366353 creator A5044141815 @default.
• W2057366353 creator A5050172817 @default.
• W2057366353 creator A5052449071 @default.
• W2057366353 creator A5054642128 @default.
• W2057366353 creator A5066355606 @default.
• W2057366353 creator A5068961742 @default.
• W2057366353 creator A5070180093 @default.
• W2057366353 creator A5072389805 @default.
• W2057366353 creator A5072810218 @default.
• W2057366353 creator A5084753857 @default.
• W2057366353 creator A5085369220 @default.
• W2057366353 creator A5087308492 @default.
• W2057366353 date "2014-11-17" @default.
• W2057366353 modified "2023-10-18" @default.
• W2057366353 title "Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor" @default.
• W2057366353 cites W1977267072 @default.
• W2057366353 cites W1998038367 @default.
• W2057366353 cites W2000954296 @default.
• W2057366353 cites W2009886463 @default.
• W2057366353 cites W2021145743 @default.
• W2057366353 cites W2026842712 @default.
• W2057366353 cites W2070732456 @default.
• W2057366353 cites W2070765493 @default.
• W2057366353 cites W2087693130 @default.
• W2057366353 cites W2093128131 @default.
• W2057366353 cites W2101982508 @default.
• W2057366353 cites W2103441770 @default.
• W2057366353 cites W2108401385 @default.
• W2057366353 cites W2113687561 @default.
• W2057366353 cites W2116343581 @default.
• W2057366353 cites W2124358769 @default.
• W2057366353 cites W2129172946 @default.
• W2057366353 cites W2130940380 @default.
• W2057366353 cites W2137618229 @default.
• W2057366353 cites W2138601221 @default.
• W2057366353 cites W2139248078 @default.
• W2057366353 cites W2139790154 @default.
• W2057366353 cites W2148066973 @default.
• W2057366353 cites W2150575159 @default.
• W2057366353 cites W2153096480 @default.
• W2057366353 cites W2159581459 @default.
• W2057366353 cites W2168133698 @default.
• W2057366353 doi "https://doi.org/10.1038/nature13948" @default.
• W2057366353 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4326538" @default.
• W2057366353 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25409150" @default.
• W2057366353 hasPublicationYear "2014" @default.
• W2057366353 type Work @default.
• W2057366353 sameAs 2057366353 @default.
• W2057366353 citedByCount "454" @default.
• W2057366353 countsByYear W20573663532014 @default.
• W2057366353 countsByYear W20573663532015 @default.
• W2057366353 countsByYear W20573663532016 @default.
• W2057366353 countsByYear W20573663532017 @default.
• W2057366353 countsByYear W20573663532018 @default.
• W2057366353 countsByYear W20573663532019 @default.
• W2057366353 countsByYear W20573663532020 @default.
• W2057366353 countsByYear W20573663532021 @default.
• W2057366353 countsByYear W20573663532022 @default.
• W2057366353 countsByYear W20573663532023 @default.
• W2057366353 crossrefType "journal-article" @default.
• W2057366353 hasAuthorship W2057366353A5002819777 @default.
• W2057366353 hasAuthorship W2057366353A5003417891 @default.
• W2057366353 hasAuthorship W2057366353A5004300577 @default.
• W2057366353 hasAuthorship W2057366353A5004669792 @default.
• W2057366353 hasAuthorship W2057366353A5007116190 @default.
• W2057366353 hasAuthorship W2057366353A5011125370 @default.
• W2057366353 hasAuthorship W2057366353A5018555557 @default.
• W2057366353 hasAuthorship W2057366353A5019032346 @default.
• W2057366353 hasAuthorship W2057366353A5023891950 @default.
• W2057366353 hasAuthorship W2057366353A5025451142 @default.
• W2057366353 hasAuthorship W2057366353A5033930240 @default.
• W2057366353 hasAuthorship W2057366353A5034256147 @default.
• W2057366353 hasAuthorship W2057366353A5035700326 @default.
• W2057366353 hasAuthorship W2057366353A5037092952 @default.
• W2057366353 hasAuthorship W2057366353A5042749420 @default.
• W2057366353 hasAuthorship W2057366353A5044141815 @default.
• W2057366353 hasAuthorship W2057366353A5050172817 @default.
• W2057366353 hasAuthorship W2057366353A5052449071 @default.
• W2057366353 hasAuthorship W2057366353A5054642128 @default.
• W2057366353 hasAuthorship W2057366353A5066355606 @default.
• W2057366353 hasAuthorship W2057366353A5068961742 @default.

• next